Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
Huntington DiseaseThis is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.
Move to Improve: Telehealth Exercise to Music for HD
Huntington DiseaseThe purpose of this study is to determine if a movement to music exercise program delivered via telehealth is feasible and safe for individuals with neurodegenerative disease and their caregivers (Aim 1). A secondary aim will be to determine if a movement to music exercise program delivered via telehealth improves balance, cognition, mobility, and quality of life (Aim 2).
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease...
Huntington DiseaseThe primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's...
Huntington's DiseaseThe primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease
Huntington DiseaseEvaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the central nervous system of these patients using as the main biomarker the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year. Our main hypothesis is that combined thiamine-biotin oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea...
ChoreaHuntingtonThis is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
TEsting METformin Against Cognitive Decline in HD
Huntington DiseaseMulticenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease. The study consists of a screening period (2 to 4 weeks), followed by a 52-week double-blind treatment period and a follow-up visit (one month after the end of treatment).
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Huntington DiseaseThe primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Huntington DiseaseExamine the effects of deutetrabenazine on functional speech and gait impairment
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
Spinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 31 moreThe goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.